6361.5000 -234.00 (-3.55%)
NSE Aug 01, 2025 15:31 PM
Volume: 467.2K
 

6361.50
-3.55%
Motilal Oswal
Divi's Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space at least sixteen molecules are under various phases of development and in the subsequent DMF filing stage. Particularly, we find DIVI's work interesting in the Contrast Media segment. While there is complexity associated with Iodine-based products, DIVI's strong chemistry skill set and experience in the Contrast Media space have enabled it to bring the Iohexol API to the validation phase. We believe DIVI is well-placed to capitalize on the carotenoid opportunity, with a...
Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.
More from Divi's Laboratories Ltd.
Recommended